DK3370697T3 - Fysisk og kemisk stabile orale suspensioner af givinostat - Google Patents
Fysisk og kemisk stabile orale suspensioner af givinostat Download PDFInfo
- Publication number
- DK3370697T3 DK3370697T3 DK16805507.7T DK16805507T DK3370697T3 DK 3370697 T3 DK3370697 T3 DK 3370697T3 DK 16805507 T DK16805507 T DK 16805507T DK 3370697 T3 DK3370697 T3 DK 3370697T3
- Authority
- DK
- Denmark
- Prior art keywords
- givinostat
- physical
- oral suspensions
- stable oral
- chemical stable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITUB2015A005193A ITUB20155193A1 (it) | 2015-11-03 | 2015-11-03 | Sospensioni orali di Givinostat fisicamente e chimicamente stabili |
| PCT/IB2016/056496 WO2017077436A1 (en) | 2015-11-03 | 2016-10-28 | Physically and chemically stable oral suspensions of givinostat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3370697T3 true DK3370697T3 (da) | 2021-04-26 |
Family
ID=55410062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16805507.7T DK3370697T3 (da) | 2015-11-03 | 2016-10-28 | Fysisk og kemisk stabile orale suspensioner af givinostat |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US10688047B2 (da) |
| EP (1) | EP3370697B1 (da) |
| JP (1) | JP6800970B2 (da) |
| KR (1) | KR102603894B1 (da) |
| CN (2) | CN113368044B (da) |
| AR (1) | AR106559A1 (da) |
| AU (1) | AU2016349169B2 (da) |
| BR (1) | BR122024001653A2 (da) |
| CA (1) | CA3002755C (da) |
| CL (1) | CL2018001151A1 (da) |
| CO (1) | CO2018003971A2 (da) |
| CY (1) | CY1124092T1 (da) |
| DK (1) | DK3370697T3 (da) |
| ES (1) | ES2870201T3 (da) |
| HK (1) | HK1254811A1 (da) |
| HR (1) | HRP20210747T1 (da) |
| HU (1) | HUE054123T2 (da) |
| IL (1) | IL258608B (da) |
| IT (1) | ITUB20155193A1 (da) |
| LT (1) | LT3370697T (da) |
| MX (1) | MX2018004505A (da) |
| NZ (1) | NZ741467A (da) |
| PE (1) | PE20181369A1 (da) |
| PL (1) | PL3370697T3 (da) |
| PT (1) | PT3370697T (da) |
| RS (1) | RS61694B1 (da) |
| RU (1) | RU2721396C2 (da) |
| SI (1) | SI3370697T1 (da) |
| TW (1) | TWI727983B (da) |
| WO (1) | WO2017077436A1 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020283590A1 (en) | 2019-05-31 | 2022-01-20 | Viracta Subsidiary, Inc. | Methods of treating virally associated cancers with histone deacetylase inhibitors |
| WO2022088037A1 (zh) * | 2020-10-30 | 2022-05-05 | 中国科学院深圳先进技术研究院 | Sirtinol在制备预防和治疗冠状病毒的药物中的应用 |
| CN114306311A (zh) * | 2022-01-14 | 2022-04-12 | 同济大学 | 组蛋白去乙酰化酶抑制剂在制备治疗心脏病的药物中的应用 |
| CN116173003A (zh) * | 2023-02-24 | 2023-05-30 | 山西医科大学 | 药物吉维司他在治疗阿尔茨海默病中的用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4169150A (en) * | 1975-11-12 | 1979-09-25 | Teijin Limited | Benzodiazepine derivatives and pharmaceutical compositions containing said derivatives |
| DE3902079A1 (de) * | 1988-04-15 | 1989-10-26 | Bayer Ag | I.m. injektionsformen von gyrase-inhibitoren |
| US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| DE4200821A1 (de) * | 1992-01-15 | 1993-07-22 | Bayer Ag | Geschmacksmaskierte pharmazeutische mittel |
| IT1283637B1 (it) | 1996-05-14 | 1998-04-23 | Italfarmaco Spa | Composti ad attivita' antinfiammatoria ed immunosoppressiva |
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| JP4975941B2 (ja) | 2000-09-29 | 2012-07-11 | トポターゲット ユーケー リミテッド | （ｅ）−ｎ−ヒドロキシ−３−（３−スルファモイル−フェニル）アクリルアミド化合物及びその治療用途 |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| JP2005516943A (ja) * | 2001-12-20 | 2005-06-09 | ファルマシア コーポレーション | 経口投与に適した医薬品懸濁液 |
| CN100445276C (zh) | 2002-03-13 | 2008-12-24 | 詹森药业有限公司 | 用作组蛋白去乙酰酶抑制剂的磺酰基衍生物 |
| ITMI20030063A1 (it) | 2003-01-17 | 2004-07-18 | Italfarmaco Spa | Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico. |
| US7244751B2 (en) | 2003-02-14 | 2007-07-17 | Shenzhen Chipscreen Biosciences Ltd. | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity |
| AU2004230889B2 (en) | 2003-04-07 | 2008-03-13 | Pharmacyclics Llc | Hydroxamates as therapeutic agents |
| WO2005019174A1 (en) | 2003-08-20 | 2005-03-03 | Axys Pharmaceuticals, Inc. | Acetylene derivatives as inhibitors of histone deacetylase |
| ITMI20041347A1 (it) | 2004-07-05 | 2004-10-05 | Italfarmaco Spa | Derivati di alfa-amminoacidi ad attivita'antiinfiammatoria |
| EP1781639B1 (en) | 2004-07-28 | 2012-01-25 | Janssen Pharmaceutica NV | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
| WO2006018814A2 (en) * | 2004-08-16 | 2006-02-23 | Ranbaxy Laboratories Limited | Oral liquid suspensions of metaxalone |
| WO2007135362A2 (en) * | 2006-05-19 | 2007-11-29 | Norbrook Laboratories Limited | Stable aqueous suspension having palatable taste |
| JP2010502743A (ja) | 2006-09-11 | 2010-01-28 | キュリス，インコーポレイテッド | 抗増殖薬剤としての多機能性低分子 |
| US8263652B2 (en) * | 2007-10-31 | 2012-09-11 | Sk Biopharmaceuticals Co., Ltd. | Stabilized pediatric suspension of carisbamate |
| EP2228054A1 (en) * | 2009-03-13 | 2010-09-15 | ITALFARMACO S.p.A. | Riluzole aqueous suspensions |
| JP2013509435A (ja) * | 2009-10-30 | 2013-03-14 | ヤンセン ファーマシューティカ エヌ．ベー． | 長時間作用型注入可能パリペリドンエステルに関連した投与レジメン |
| IT1397912B1 (it) * | 2010-01-28 | 2013-02-04 | Chemi Spa | Nuovo polimorfo dell'estere 6-dietilamminometil-2-naftilico dell'acido 4-idrossicarbamoil-fenil-carbammico cloridrato. |
| WO2011113013A2 (en) * | 2010-03-11 | 2011-09-15 | Hemaquest Pharmaceuticals, Inc. | Methods and compositions for treating viral or virally-induced conditions |
| TW201245115A (en) * | 2011-01-24 | 2012-11-16 | Chdi Foundation Inc | Histone deacetylase inhibitors and compositions and methods of use thereof |
| CN107007580A (zh) * | 2012-02-03 | 2017-08-04 | 意大发马克股份公司 | 用于治疗肌肉萎缩症的化合物 |
| EP2968080B1 (en) * | 2013-03-12 | 2023-05-10 | Synedgen, Inc. | Oral formulation of polyglucosamine derivatives in combination with a non-fermentable sugar |
| US9783488B2 (en) * | 2013-03-14 | 2017-10-10 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| WO2015086738A2 (en) | 2013-12-11 | 2015-06-18 | Bionor Immuno As | Hiv vaccine |
-
2015
- 2015-11-03 IT ITUB2015A005193A patent/ITUB20155193A1/it unknown
-
2016
- 2016-10-20 TW TW105133874A patent/TWI727983B/zh active
- 2016-10-28 MX MX2018004505A patent/MX2018004505A/es unknown
- 2016-10-28 RU RU2018120170A patent/RU2721396C2/ru active
- 2016-10-28 DK DK16805507.7T patent/DK3370697T3/da active
- 2016-10-28 PL PL16805507T patent/PL3370697T3/pl unknown
- 2016-10-28 PT PT168055077T patent/PT3370697T/pt unknown
- 2016-10-28 ES ES16805507T patent/ES2870201T3/es active Active
- 2016-10-28 RS RS20210421A patent/RS61694B1/sr unknown
- 2016-10-28 NZ NZ741467A patent/NZ741467A/en unknown
- 2016-10-28 LT LTEP16805507.7T patent/LT3370697T/lt unknown
- 2016-10-28 US US15/770,443 patent/US10688047B2/en active Active
- 2016-10-28 EP EP16805507.7A patent/EP3370697B1/en active Active
- 2016-10-28 CA CA3002755A patent/CA3002755C/en active Active
- 2016-10-28 CN CN202110722868.2A patent/CN113368044B/zh active Active
- 2016-10-28 AU AU2016349169A patent/AU2016349169B2/en active Active
- 2016-10-28 KR KR1020187014706A patent/KR102603894B1/ko active IP Right Grant
- 2016-10-28 JP JP2018522990A patent/JP6800970B2/ja active Active
- 2016-10-28 PE PE2018000576A patent/PE20181369A1/es unknown
- 2016-10-28 WO PCT/IB2016/056496 patent/WO2017077436A1/en active Application Filing
- 2016-10-28 BR BR122024001653-2A patent/BR122024001653A2/pt unknown
- 2016-10-28 HU HUE16805507A patent/HUE054123T2/hu unknown
- 2016-10-28 CN CN201680062179.0A patent/CN108366956B/zh active Active
- 2016-10-28 SI SI201631132T patent/SI3370697T1/sl unknown
- 2016-11-02 AR ARP160103344A patent/AR106559A1/es unknown
-
2018
- 2018-04-10 IL IL258608A patent/IL258608B/en unknown
- 2018-04-13 CO CONC2018/0003971A patent/CO2018003971A2/es unknown
- 2018-04-30 CL CL2018001151A patent/CL2018001151A1/es unknown
- 2018-10-31 HK HK18113898.6A patent/HK1254811A1/zh unknown
-
2021
- 2021-05-07 CY CY20211100388T patent/CY1124092T1/el unknown
- 2021-05-12 HR HRP20210747TT patent/HRP20210747T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3595653T3 (da) | Sammensætninger af plinabulin og anvendelse heraf | |
| DK3429596T3 (da) | Cykliske dinukleotide forbindelser og brugs metoder | |
| DK3259253T3 (da) | Sulfonylureaer og relaterede forbindelser og brug af samme | |
| DK3448386T3 (da) | Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf | |
| DK3289168T3 (da) | Forsegling og aktivering af borehul | |
| DK3291679T3 (da) | Ændring af mikrobielle populationer og modificering af mikrobiota | |
| DK3283107T3 (da) | Sammensætninger omfattende en kombination af ipilimumab og nivolumab | |
| DK3160470T3 (da) | Analoger af pridopidin, fremstilling og anvendelse heraf | |
| DK3557998T3 (da) | Sammensætninger, kompositioner og anvendelsesmetoder | |
| DK3288553T3 (da) | Kombinationer af cannabinoider og n-acylethanolaminer | |
| DK3509581T3 (da) | Formuleringer af (r)-2-amino-3-phenylpropylcarbamat | |
| DK3325662T3 (da) | Epigenetisk inaktivering af nmt2 | |
| DK3364958T3 (da) | Modulatorer af sestrin-gator2-interaktion og anvendelser deraf | |
| DK3510049T3 (da) | Varianter af sur alfa-glucosidase og anvendelser deraf | |
| DK3457851T3 (da) | Derivater af sobetirom | |
| DK3129019T3 (da) | Medicinsk anvendelse af artemisinin-forbindelser og gephyrin-agonister | |
| DK3331879T3 (da) | Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne | |
| DK3282373T3 (da) | Validering og integration af samarbejdningsregnearksdata | |
| DK3307267T3 (da) | Behandling af multipel sklerose | |
| DK3319609T3 (da) | Sammensætninger og fremgangsmåder til anvendelse af antibakterielle lægemiddelkombinationer | |
| DK3347006T3 (da) | Deutererede analoger af etifoxin, derivater deraf og anvendelser deraf | |
| DK3197433T3 (da) | Stabile formuleringer af lipider og liposomer | |
| DK3427014T3 (da) | Flowrørsindsats og anvendelse af flowrørsindsats | |
| DK3265126T3 (da) | Kombinationsformulering af tesofensin og metoprolol | |
| DK3390422T3 (da) | Krystalformer af lnt |